NCT00753909已完成2 期
Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer
Hellenic Oncology Research Group10 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
- 试验地点
- 10
- 主要终点
- Overall Response Rate
研究概览
简要总结
This trial will evaluate the efficacy and safety of paclitaxel, carboplatin and bevacizumab combination, administered biweekly, in patients with pretreated, advanced non small cell lung cancer.
详细描述
The addition of bevacizumab to paclitaxel plus carboplatin in the 1st line treatment of patients with advanced or metastatic non small cell lung cancer (NSCLC) provided a survival benefit. There are patients with NSCLC who have not received bevacizumab and have relapsed after 1st and/or 2nd line therapy. The evaluation of bevacizumab plus chemotherapy in such patients is justified. The combination of paclitaxel and carboplatin, administered every two weeks, has a favorable toxicity profile. This study will evaluate the addition of bevacizumab to a biweekly regimen of paclitaxel and carboplatin as 2nd or 3rd line therapy for NSCLC
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB) or metastatic (stage IV) non-squamous NSCLC
- •Non-squamous histologic type
- •At least one and no more than two previous chemotherapy regimens for advanced or metastatic NSCLC
- •Measurable disease, defined as at least 1 bidimensionally measurable lesion ≥ 20 X 10 mm.
- •Age ≥ 18 years
- •Performance status (WHO) 0-2
- •Life expectancy of at least 12 weeks
- •Adequate bone marrow (ANC ≥ 1,500/mm3, PLT ≥ 100,000/mm3, Hgb ≥ 9 g/dL), liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 2.5 upper normal limit in the absence of liver metastases or ≤ 5 upper normal limit in the presence of liver metastases), and renal function (Creatinine ≤ 1,5 upper normal limit)
- •Patients must be able to understand the nature of this study
- •Written informed consent
排除标准
- •Previous therapy with paclitaxel in combination with carboplatin
- •Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
- •Pregnant or lactating women
- •Any serious, uncontrolled comorbidity on the investigator's judgment
- •Uncontrolled infection
- •Any sustained chronic toxicity > grade 2 according to the NCI CTCAE (version 3.0)
- •Symptomatic neuropathy > grade 2 according to the NCI CTCAE (version 3.0)
- •Brain metastases, except if radiated and asymptomatic
- •Radiotherapy within the previous 4 weeks
- •Previous radiotherapy to the only measurable lesion
- •Proteinuria ≥ 500 mgr of protein daily
- •Hemoptysis > 10 cc per event
- •Clinically significant hematemesis
- •Centrally located lesion or in contact with major vessels
- •Pulmonary lesion with cavitation
- •Documented hemorrhagic diathesis or coagulation disorder
- •Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial infarction within the previous 4 months, unstable angina, LVEF < normal, ventricular arrhythmia, uncontrolled hypertension)
- •Thrombotic event within the previous 6 months
- •Concurrent use of aspirin > 325 mgr daily, low molecular weight heparin in therapeutic dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents
- •Concurrent treatment with other anti-cancer drug
- •Major surgical procedure within the previous 4 weeks
研究组 & 干预措施
1
Experimental
Paclitaxel/Carboplatin/Bevacizumab
干预措施: Carboplatin (Drug)
1
Experimental
Paclitaxel/Carboplatin/Bevacizumab
干预措施: Bevacizumab (Drug)
1
Experimental
Paclitaxel/Carboplatin/Bevacizumab
干预措施: Paclitaxel (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)
次要结局
- Toxicity profile(Toxicity assessment of each chemotherapy cycle)
- Time to Tumor Progression(1-year)
- Overall Survival(1 year)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid AdenocarcinomaFallopian Tube Mucinous AdenocarcinomaFallopian Tube Serous AdenocarcinomaFallopian Tube Transitional Cell CarcinomaMalignant Ovarian Mixed Epithelial TumorOvarian Brenner TumorOvarian Clear Cell AdenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mucinous AdenocarcinomaOvarian Serous AdenocarcinomaOvarian Transitional Cell CarcinomaPrimary Peritoneal Serous AdenocarcinomaStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Primary Peritoneal CancerStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerUndifferentiated Fallopian Tube CarcinomaUndifferentiated Ovarian CarcinomaNCT00262847National Cancer Institute (NCI)1,873
终止
1 期
Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung CancerAdenocarcinoma of the LungBronchoalveolar Cell Lung CancerLarge Cell Lung CancerStage II Non-small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerNCT00369551National Cancer Institute (NCI)36
已完成
1 期
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast CancerBreast CancerNCT00691379Hellenic Oncology Research Group46
已完成
2 期
Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the BladderBladder CancerNCT00136175University of Michigan Rogel Cancer Center68
已完成
2 期
Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00578149Dana-Farber Cancer Institute45